PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Oman

PharmaMar (MSE:PHM) today announced that its partner , Immedica Pharma AB (Immedica), has received full marketing approval for Zepzelca from the Omani Ministry of Health for the treatment of adult cancer patients. metastatic small cell lung disease with disease progression during or after platinum-based chemotherapy.

This new approval is based on clinical data from the single-arm, multicenter, open-label monotherapy trial in 105 adult patients with recurrent metastatic small cell lung cancer (including patients with platinum-sensitive and platinum-resistant disease), which the Food and Drug Administration (FDA) used to grant accelerated approval for lurbinectedin in the United States.

PharmaMar and Immedica signed a strategic alliance in 2020 for the exclusive distribution and marketing of lurbinectedin for different territories that include the United Kingdom, Ireland, the Nordic countries, some countries in Eastern Europe, the Middle East and North Africa.

About 15% of all lung cancers are small cell or small cell lung cancer. This type of lung cancer usually grows and spreads faster than non-small cell lung cancer. In most people with small cell lung cancer, the cancer has spread beyond the lungs by the time it is diagnosed [1] .

Contact:

Tel: +34 91 846 6000

Fax: 91 846 6001

Email: pharmamar@pharmamar.com